Navigation Links
Novel discovery by NUS scientists paves the way for more effective treatment of cancers
Date:5/21/2012

A team of scientists from the National University of Singapore's (NUS) Department of Biological Sciences and Mechanobiology Institute have discovered how a drug-led compound a compound that is undergoing preclinical trials as a potential drug can deprive cancer cells of energy and stop them from growing into a tumour. This drug-led compound is named BPTES.

This is the first time a research group has provided evidence showing how a drug-lead compound suppresses tumour formation.

Building on the new findings, the NUS team also derived positive results for a novel dual-drug treatment regime involving BPTES that kills kidney and breast cancer cells more effectively.

The team led by Associate Professor Low Boon Chuan and Associate Professor Jayaraman Sivaraman first published their findings in the journal of Proceedings of the National Academy of Sciences (PNAS) on 26 April 2012.

Killing cancer cells by 'starving' them of energy

Classic experiments in cancer biology have demonstrated that cancer cells feed off the breakdown of the amino acid glutamine to gain energy and grow into a tumour. While it is known that human glutaminase is the first enzyme in catalysing this series of biochemical reactions, little is known about how its activity is controlled, and how it can be manipulated.

The NUS research team has successfully identified the mechanism in which the BPTES that can bind and inhibit glutaminase, can effectively starve the cancer cells of their energy source, and hence, could potentially prevent tumour growth.

In addition, the team has also found that the glutaminase activity can be activated upon the addition of phosphate by epidermal growth factor signaling a pathway that controls cancer cells proliferation. By using another inhibitor to block the kinase Mek2 within this cancer-causing pathway, coupled with the use of BPTES, the combined therapeutic effect is more potent and less toxic. This raises the hope of offering a new dual-drug cancer treatment regime for cancers such as lymphoma, prostate, glioblastoma, breast and kidney cancer cells that is more effective and with fewer side-effects.

The Next Step

Armed with structural insights into the binding and signaling pathway that activates glutaminase, the NUS research team is conducting more studies to determine whether a combination of drugs would be even more effective in inhibiting glutaminase activity and hence, tumour formation.

Using the knowledge that they gained through their current studies, the research team will also look into optimising the tumour suppression property of BPTES to increase its efficiency and lower its side-effects.


'/>"/>
Contact: Carolyn Fong
carolyn@nus.edu.sg
65-651-65399
National University of Singapore
Source:Eurekalert

Related biology news :

1. Scientists identify novel inhibitor of human microRNA
2. Conaway Lab identifies novel mechanism for regulation of gene expression
3. LIAI launches new division to look at novel approaches to heart disease and inflammation
4. Childrens National researchers develop novel anti-tumor vaccine
5. Cold Spring Harbor Laboratory scientists trace a novel way cells are disrupted in cancer
6. Novel publishing approach puts textbook in more hands
7. GEN reports on novel tools for deciphering biological networks
8. UT Southwestern researcher awarded Gates Foundation grant for novel vaccine development
9. 3-substituted indolones as novel therapeutic compounds for neurodegenerative conditions
10. Corn researchers discover novel gene shut-off mechanisms
11. A novel target for therapeutics against Staph infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/9/2016)... , June 9, 2016 ... Police deploy Teleste,s video security solution to ensure the safety ... France during the major tournament Teleste, ... communications systems and services, announced today that its video security ... to back up public safety across the country. ...
(Date:6/2/2016)... 2016 Perimeter Surveillance & Detection ... Physical Infrastructure, Support & Other Service  The ... offers comprehensive analysis of the global Border Security ... revenues of $17.98 billion in 2016. Now: ... leader in software and hardware technologies for advanced video ...
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
(Date:6/23/2016)... ... 23, 2016 , ... STACS DNA Inc., the sample tracking software company, today ... Laboratory, has joined STACS DNA as a Field Application Specialist. , “I am ... and COO of STACS DNA. “In further expanding our capacity as a scientific integrator, ...
(Date:6/23/2016)... -- On Wednesday, June 22, 2016, the NASDAQ ... Dow Jones Industrial Average edged 0.27% lower to finish at ... Stock-Callers.com has initiated coverage on the following equities: Infinity Pharmaceuticals ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ... Learn more about these stocks by accessing their free trade ...
(Date:6/23/2016)... , June 23, 2016 ... research report to its pharmaceuticals section with historic ... details and much more. Complete report ... 151 pages, profiling 15 companies and supported with ... http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . The Global ...
Breaking Biology Technology: